<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSM1088405"><item key="SHRNA">shSTAT1</item></item></item><item><item key="GSM1088405"><item key="SHRNA">shSTAT1</item></item></item><item><item key="GSM1088405"><item key="SHRNA">shSTAT1</item></item></item><item><item key="GSM1088405"><item key="SHRNA">shSTAT1</item></item></item><item><item key="GSM108840"><item key="SHRNA">shTYK2</item></item></item><item><item key="GSM108840"><item key="SHRNA">shTYK2</item></item></item><item><item key="GSM108840"><item key="SHRNA">shTYK2</item></item></item><item><item key="GSM108840"><item key="SHRNA">shTYK2</item></item></item><item><item key="GSM1088397"><item key="SHRNA">shLuc</item></item></item><item><item key="GSM1088397"><item key="SHRNA">shLuc</item></item></item><item><item key="GSM1088395"><item key="SHRNA">shGFP</item></item></item><item><item key="GSM1088395"><item key="SHRNA">shGFP</item></item></item></item><item key="id">2504</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many...</item><item key="geo_gse_id">E-GEOD-44652</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">1</item><item key="sample_count">12</item><item key="tags"><item>acute lymphoblastic leukemia</item><item>cell</item><item>leukemia</item><item>line</item><item>lymphoblastic leukemia</item><item>protein</item><item>tyrosine</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">gene-expression-profile-of-the-human-t-all-cell-li</item><item key="geo_id_plat">E-GEOD-44652_A-AFFY-44</item><item key="name">Gene expression profile of the human T-ALL cell line JURKAT after TYK2 and STAT1 knockdown</item><item key="created">Jul.12, 2014</item><item key="summary">Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the JAK tyrosine kinase family, TYK2, and its downstream effector STAT1 in T-cell acute lymphoblastic leukemia (T-ALL). Gene knockdown experiments consistently demonstrated TYK2 dependence in both T-ALL primary specimens and cell lines, and a small-molecule inhibitor of JAK kinase activity induced T-ALL cell death. Activation of this TYK2-STAT1 pathway in T-ALL cell lines occurs by gain-of-function TYK2 mutations or activation of IL-10 receptor signaling, and this pathway mediates T-ALL cell survival through upregulation of the anti-apoptotic protein BCL2. These findings indicate that in many T-ALL cases, the leukemic cells are dependent upon the TYK2-STAT1-BCL2 pathway for continued survival, supporting the development of molecular therapies targeting TYK2 and other components of this pathway. Human T-ALL cell line JURKAT cells were transduced with TYK2 (TYK2#2 or #3), STAT1 (STAT1#2 or #3) or control shRNAs (GFP and Luc). Experiment was done in biological duplicate ("dup1" and "dup2") . A total of 12 RNA samples (4 control, 4 TYK2 knockdown and 4 STAT1 knockdown) were used for microarray gene expression analysis.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-44652</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-44652/samples/</item></data></biogps>
